enGene Holdings Inc. (ENGN)

15.32 -0.57 (-3.59%) At close: 04:00PM EDT

enGene Holdings Inc.

7171 Rue Frederick Banting
Saint-Laurent, QC H4S 1Z9
Canada
514 332 4888
https://www.engene.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 31

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jason D. Hanson Esq., J.D.	CEO & Director	656.58k	N/A	1969
Dr. Alex Nichols Ph.D.	President & COO	504.44k	N/A	1986
Dr. James C. Sullivan M.Sc., Ph.D.	Chief Scientific Officer	524.29k	N/A	1979
Dr. Anthony T. Cheung Ph.D.	Co-Founder & CTO	341.75k	N/A	1972
Mr. John C. Brown D.Sc., FRSC, Ph.D.	Co-Founder and Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. David Ryan Daws	CFO & Head of Business Development	N/A	N/A	1974
Mr. Lee G. Giguere	Chief Legal Officer & Corporate Secretary	N/A	N/A	1981
Ms. Sharon Tan	VP of Project Management & Head of Program Management	N/A	N/A	N/A
Dr. Richard P. Bryce MBChB, MFPM, MRCGP	Chief Medical Officer	N/A	N/A	1957
Dr. Raj Pruthi M.D.	Senior VP of Urologic Oncology & Clinical Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Corporate governance

enGene Holdings Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.